Research ExplorerPublicationsNeue Aspekte der primären Radiochemotherapie bei Kopf-Hals-T...

Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011

Standard

Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011. / Laban, S; Wang, C J; Knecht, R; Tribius, S; Münscher, A.

In: HNO, Vol. 60, No. 5, 01.05.2012, p. 393-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Laban, S, Wang, CJ, Knecht, R, Tribius, S & Münscher, A 2012, 'Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011', HNO, vol. 60, no. 5, pp. 393-7. https://doi.org/10.1007/s00106-011-2463-0

APA

Laban, S., Wang, C. J., Knecht, R., Tribius, S., & Münscher, A. (2012). Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011. HNO, 60(5), 393-7. https://doi.org/10.1007/s00106-011-2463-0

Vancouver

Laban S, Wang CJ, Knecht R, Tribius S, Münscher A. Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011. HNO. 2012 May 1;60(5):393-7. https://doi.org/10.1007/s00106-011-2463-0

Bibtex

@article{406ba5047f4e4a0d91a305ce84167aef,
title = "Neue Aspekte der prim{\"a}ren Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011",
abstract = "Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.",
keywords = "Antineoplastic Agents, Chemoradiotherapy, Germany, Head and Neck Neoplasms, Humans, Radiotherapy, Conformal",
author = "S Laban and Wang, {C J} and R Knecht and S Tribius and A M{\"u}nscher",
year = "2012",
month = may,
day = "1",
doi = "10.1007/s00106-011-2463-0",
language = "Deutsch",
volume = "60",
pages = "393--7",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011

AU - Laban, S

AU - Wang, C J

AU - Knecht, R

AU - Tribius, S

AU - Münscher, A

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.

AB - Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.

KW - Antineoplastic Agents

KW - Chemoradiotherapy

KW - Germany

KW - Head and Neck Neoplasms

KW - Humans

KW - Radiotherapy, Conformal

U2 - 10.1007/s00106-011-2463-0

DO - 10.1007/s00106-011-2463-0

M3 - SCORING: Zeitschriftenaufsatz

C2 - 22570002

VL - 60

SP - 393

EP - 397

JO - HNO

JF - HNO

SN - 0017-6192

IS - 5

ER -